文献速递食管胃疾病与幽门螺杆菌

宿主遗传因素与幽门螺杆菌根除治疗失败的系统综述与荟萃分析

Host Genetic Determinants Associated With Helicobacter pylori Eradication Treatment Failure: A Systematic Review and Meta-analysis.
PubMed 文献 · Gastroenterology · 2021-08-03

该研究系统检索并荟萃分析了57项来自11个国家的研究,评估宿主遗传多态性与幽门螺杆菌根除失败的关系。主要分析CYP2C19多态性,发现当使用主要经CYP2C19代谢的质子泵抑制剂时,快代谢型与根除失败风险显著升高相关(OR 2.52),在确认依从性和克拉霉素敏感性后风险更高(OR 4.44)。IL1B多态性也与根除失败风险升高相关(OR 1.72)。MDR1多态性无显著关联。证据确定性为中等。

要点

  • CYP2C19快代谢型使用主要经CYP2C19代谢的PPI时,根除失败风险显著增加。
  • 确认依从性和克拉霉素敏感性后,CYP2C19快代谢型与根除失败关联更强。
  • IL1B多态性与胃酸抑制减弱相关,与根除失败风险升高相关。

核心结论

  • 宿主遗传多态性与幽门螺杆菌根除治疗失败显著相关,尤其在治疗依从且抗生素敏感的个体中。

研究设计与样本

  • 系统综述与荟萃分析,纳入57项来自11个国家的研究,比较根除失败与成功组间宿主基因多态性。
  • 采用随机效应模型合并估计,并进行全面敏感性分析。

主要发现

  • 使用主要经CYP2C19代谢的PPI方案时,快代谢型 vs 慢代谢型与根除失败风险升高相关(OR 2.52,显著)。
  • 确认治疗依从性和克拉霉素敏感性后,快代谢型 vs 慢代谢型与根除失败风险升高相关(OR 4.44,显著)。
  • 使用不经或较少经CYP2C19代谢的PPI时,CYP2C19变异与根除失败无显著关联。
  • 与胃酸抑制减弱相关的IL1B多态性与根除失败风险升高相关(OR 1.72,显著)。
  • MDR1多态性与幽门螺杆菌根除失败无显著关联。

关键数值与推荐

  • CYP2C19快代谢型 vs 慢代谢型:根除失败OR 2.52(显著)。
  • 确认依从性和克拉霉素敏感性后:OR 4.44(显著)。
  • IL1B多态性(与胃酸抑制减弱相关 vs 不相关):OR 1.72(显著)。
  • 证据确定性为中等。

临床怎么用

  • 对使用主要经CYP2C19代谢PPI的患者,可考虑CYP2C19基因型指导PPI选择或剂量。
  • 在治疗依从且克拉霉素敏感的患者中,宿主遗传因素可能是根除失败的重要原因。
  • 选用不经或较少经CYP2C19代谢的PPI可能降低遗传因素导致的失败风险。

局限性

  • 多数研究分析CYP2C19多态性,其他基因数据有限。
  • 证据确定性为中等。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Helicobacter pylori infects approximately 50% of individuals worldwide. Successful H pylori eradication is associated with reduced risk of gastric cancer and peptic ulcer disease, among other conditions. We hypothesized that host genetic determinants, especially those affecting gastric pH, might contribute to eradication therapy failure, particularly when treatment adherence and antibiotic susceptibility are confirmed. We aimed to conduct a meta-analysis of host genetic variants associated with H pylori eradication failure. METHODS: We searched the literature for studies comparing posttreatment H pylori eradication failure vs success (outcome) according to host genetic polymorphisms (exposure). Reference groups were defined according to genotypes (or corresponding phenotypes) hypothesized to be associated with successful eradication. We pooled estimates using a random-effects model and performed comprehensive sensitivity analyses. RESULTS: We analyzed 57 studies from 11 countries; the vast majority analyzed CYP2C19 polymorphisms. Among individuals prescribed eradication regimens with proton pump inhibitors predominantly CYP2C19 metabolized, enhanced vs poor metabolizer phenotypes were associated with a 2.52-fold significantly higher likelihood of eradication failure and 4.44-fold significantly higher likelihood when treatment adherence and H pylori clarithromycin susceptibility (if relevant) were confirmed. There was no association between CYP2C19 variants and eradication failure if proton pump inhibitors less metabolized by or that bypass CYP2C19 metabolism were used. IL1B polymorphisms that are vs are not associated with less gastric acid suppression were associated with 1.72-fold significantly higher likelihood of eradication failure. There was no association between MDR1 polymorphisms and H pylori eradication failure. The certainty of evidence was moderate. CONCLUSION: Based on meta-analysis, we identified host genetic polymorphisms significantly associated with H pylori eradication failure; host genetics might underlie eradication failure among treatment-adherent individuals with confirmed H pylori antibiotic susceptibility.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Shah SC, Tepler A, Chung CP, et al. Host Genetic Determinants Associated With Helicobacter pylori Eradication Treatment Failure: A Systematic Review and Meta-analysis. Gastroenterology. 2021. PMID: 34358488. doi:10.1053/j.gastro.2021.07.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。